The firm has inked a debt financing agreement with Blue Owl Capital and will use the funds to launch ITM-11in the US market following approval.

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Autolus Therapeutics' autologous CD19-directed CAR T-cell therapy Aucatzyl ...

Scientists are seeking new grant opportunities, founding their own for-profit ventures, and exploring other approaches to ...

Investigators presented interim data from a Phase III trial of Lenmeldy in patients with the late juvenile form of disease at ...

Multiple first-in-human trials showed functional and biomarker improvements in early data reported at ASGCT's annual meeting.

The firms launched the global Phase II bladder cancer trial for autogene cevumeran after seeing early success in pancreatic ...

Avenzo gets FDA permission to proceed with Phase I/II trials of an EGFR/HER3 bispecific antibody and a CDK4 inhibitor in select solid tumors.

The analysis by Ontada tracked testing rates within the US Oncology Network for PD-L1, FGFR2/3, and HER2 biomarkers over 10 ...

In trials, the drug has been effective in some tumors, but researchers at the University of Turku in Finland hope to identify biomarkers to better select patients.

NEW YORK – PeproMene Bio will expand the ongoing Phase I PMB-102 study of its BAFF-R-targeted CAR T-cell therapy PMB-CT01 after showing initial efficacy in seven lymphoma patients, the firm said ...

Located at the system's hospital in St. George, Utah, the clinic intends to offer T-cell collection closer to home.

A £129 million government grant will help the firm establish new R&D centers for advancing new cancer immunotherapies including personalized mRNA vaccines.